[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366338-105":59,"doc-detail-366338-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","molecular-targets-for-therapy-the-evolving-landscape-of-epigenetic-target-molecules-and-therapies-in-myeloid-cancers-focus-on-acute-myeloid-leukemia-and-myeloproliferative-neoplasms","MOLECULAR TARGETS FOR THERAPY - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms","","Research on myeloid neoplasms has driven major advances in cancer biology, enabling mechanism-based treatments. Epigenetic dysregulation is highlighted as a common disease mechanism in myeloid cancers, where acute myeloid leukemia shows frequent mutations in epigenetic regulators. Chromatin regulators control disease-specific transcription programs and represent attractive therapeutic targets. The review summarizes chromatin-driven mechanisms and evaluates therapeutic developments, including approved drugs and agents in clinical or preclinical investigation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-targets-for-therapy-the-evolving-landscape-of-epigenetic-target-molecules-and-therapies-in-myeloid-cancers-focus-on-acute-myeloid-leukemia-and-myeloproliferative-neoplasms/366338/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-targets-for-therapy-the-evolving-landscape-of-epigenetic-target-molecules-and-therapies-in-myeloid-cancers-focus-on-acute-myeloid-leukemia-and-myeloproliferative-neoplasms/366338.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are epigenetic dysregulation and chromatin mechanisms important in myeloid cancers?","Question",{"text":113,"@type":114},"Epigenetic dysregulation is described as a common disease mechanism in myeloid cancers. Chromatin regulators govern disease-specific transcription programs, making them promising therapeutic targets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is the role of DNMT3A in DNA methylation and AML?",{"text":118,"@type":114},"DNMT3A adds methyl groups to cytosine residues and generally promotes gene silencing. DNMT3A mutations, including the common R882 variant, are linked to DNA hypomethylation and dysregulated gene expression in AML.",{"name":120,"@type":111,"acceptedAnswer":121},"How do TET2 mutations contribute to altered gene regulation in myeloid neoplasms?",{"text":122,"@type":114},"TET2 is involved in DNA demethylation by converting methylcytosine to 5-hydroxymethylcytosine. Mutations impair this process, leading to hypermethylation and abnormal gene silencing associated with adverse clinical outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366338,1790350237,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www.nature.com/leu](www.nature.com/leu Leukemia)[ Leukemia](www.nature.com/leu Leukemia)  \nREVIEW ARTICLE OPEN   \nMOLECULAR TARGETS FOR THERAPY  \nThe evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms  \nMichael W. M. Kühn1,2, Naveen Pemmaraju 3 and Florian H. Heidel 4,5 ✉  \n© The Author(s) 2025  \n\n|  |  |  |\n| --- | --- | --- |\n|  | Research on myeloid neoplasms, a ﬁeld that has been driving scientiﬁc advances in cancer for over 50 years, has yielded many discoveries that have fundamentally reshaped our understanding of cancer biology. These insights, often the product of leukemia research, have been instrumental in developing more mechanism-based treatments in the early 2000s [1] . Recognizing epigenetic dysregulation as a common disease mechanism in myeloid cancers has been groundbreaking regarding recent treatment developments that exploit chromatin-based oncogenic mechanisms. In the case of acute myeloid leukemia (AML), sequencing studies aimed at assessing the complement of genetic alterations demonstrated that more than 60% of AML cases harbored disease-driving mutations in epigenetic regulators. This high prevalence underscores the importance of epigenetic dysregulation in AML pathogenesis [2, 3] . Chromatin regulators commonly control disease-speciﬁc transcriptional programs, making them attractive therapeutic targets to manipulate neoplastic gene expression programs, particularly in myeloid neoplasms. Several drugs targeting epigenetic mechanisms and exploiting myeloid disease-speciﬁc dependencies have recently been approved for treating myeloid neoplasms. Many additional drugs are currently being investigated in clinical trials, and numerous new compound developments are being studied in preclinical studies. This manuscript will review (1) chromatin-based disease mechanisms, such as DNA methylation, chromatin regulatory complexes, and histone modiﬁcations, currently investigated for therapeutic exploitation in |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | myeloid malignancies, and (2) therapeutic developments already approved or investigated for treating these diseases. |  |\n|  | Leukemia (2025) 39:1824–1837; [https://doi.org/10.1038/s41375-025-02639-x](https://doi.org/10.1038/s41375-025-02639-x) |  |\n|  |  |  |\n\nEPIGENETIC TARGETS IN ACUTE AND CHRONIC MYELOID CANCERS  \nEnzymes involved in DNA methylation (DNMT3A, TET2, IDH1, IDH2)  \nThe ﬁrst epigenetic modiﬁcation identiﬁed, DNA Methylation, was initially linked to cellular differentiation processes [4] . The detection of global hypomethylation [5], and hypermethylated tumor suppressor genes in tumors and later discoveries that these and other epigenetic modiﬁcations may regulate gene expression marked the beginning of epigenetic therapy developments altering these modiﬁcations [6] .  \nEpigenetic modiﬁer genes such as DNMT3A (DNA methyltransferase 3 alpha) and TET2 (ten-eleven translocation 2) play pivotal roles in regulating gene expression through modiﬁcation of the DNA methylation landscape. Their alterations are frequently implicated in the pathogenesis of myeloid neoplasms, including AML, myelodysplastic neoplasia (MDS), and myeloproliferative neoplasms (MPNs) . Understanding the function and the impact of  \nmutations in these genes helps elucidate the complex mechanisms underlying myeloid malignancies and provides insights into potential therapeutic targets.  \nDNMT3A functions as a DNA methyltransferase that adds methyl groups to cytosine residues in DNA [7] . This methylation generally leads to gene silencing. DNMT3A mutations are among the most common genetic alterations observed in AML, found in approximately 20–30% of cases [3, 8] . These mutations typically result in a loss of function, leading to DNA hypomethylation and subsequent dysregulation of gene","cbCailOfbr9hJ8UE","https://ap.wps.com/l/cbCailOfbr9hJ8UE","pdf",1207711,14,"English","# Molecular targets for therapy\n## Epigenetic targets in acute and chronic myeloid cancers\n## Enzymes involved in DNA methylation (DNMT3A, TET2, IDH1, IDH2)","[{\"question\":\"Why are epigenetic dysregulation and chromatin mechanisms important in myeloid cancers?\",\"answer\":\"Epigenetic dysregulation is described as a common disease mechanism in myeloid cancers. Chromatin regulators govern disease-specific transcription programs, making them promising therapeutic targets.\"},{\"question\":\"What is the role of DNMT3A in DNA methylation and AML?\",\"answer\":\"DNMT3A adds methyl groups to cytosine residues and generally promotes gene silencing. DNMT3A mutations, including the common R882 variant, are linked to DNA hypomethylation and dysregulated gene expression in AML.\"},{\"question\":\"How do TET2 mutations contribute to altered gene regulation in myeloid neoplasms?\",\"answer\":\"TET2 is involved in DNA demethylation by converting methylcytosine to 5-hydroxymethylcytosine. Mutations impair this process, leading to hypermethylation and abnormal gene silencing associated with adverse clinical outcomes.\"}]","MOLECULAR TARGETS FOR THERAPY - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms | PDF",1790164884,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7353713953cbf5b266672a3148bdf64.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91468c56748939a1c01c5d8025ee74bf.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45c02e96744566f3a78838870f548675.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c6eca50f3533f3e321dc33beece628e.webp",980,1301]